Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Antag Therapeutics ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   15.8% 8.5% 13.2% 6.6% 8.4% 14.4% 19.3% 19.3%   Credit score (0-100)   13 30 17 35 28 14 7 7   Credit rating   BB BB BB BBB BB BB B B   Credit limit (kDKK)   0.0 0.0 -0.0 0.0 0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -3,124 -7,867 -10,925 -13,826 -9,904 -13,708 0.0 0.0   EBITDA   -5,651 -11,359 -14,618 -15,738 -11,406 -15,999 0.0 0.0   EBIT   -5,651 -11,372 -14,645 -15,772 -11,440 -16,032 0.0 0.0   Pre-tax profit (PTP)   -5,686.8 -11,836.0 -14,972.8 -17,458.7 -11,997.4 -16,971.1 0.0 0.0   Net earnings   -4,429.2 -9,232.2 -12,353.3 -14,863.3 -9,784.4 -13,811.4 0.0 0.0   Pre-tax profit without non-rec. items   -5,687 -11,836 -14,973 -17,459 -11,997 -16,971 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 117 114 79.9 46.1 13.0 0.0 0.0   Shareholders equity total   11,816 2,584 -9,769 10,858 4,639 -9,173 -9,308 -9,308   Interest-bearing liabilities   0.0 10,652 24,530 8,671 9,106 30,015 9,308 9,308   Balance sheet total (assets)   12,714 14,116 15,721 20,671 17,564 23,970 0.0 0.0   Net Debt   -11,109 178 11,931 -8,870 -3,890 10,609 9,308 9,308     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -3,124 -7,867 -10,925 -13,826 -9,904 -13,708 0.0 0.0   Gross profit growth   16.0% -151.9% -38.9% -26.6% 28.4% -38.4% 0.0% 0.0%   Employees   4 4 7 2 2 2 0 0   Employee growth %   100.0% 0.0% 75.0% -71.4% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   12,714 14,116 15,721 20,671 17,564 23,970 0 0   Balance sheet change%   26.0% 11.0% 11.4% 31.5% -15.0% 36.5% -100.0% 0.0%   Added value   -5,651.5 -11,359.2 -14,618.2 -15,738.3 -11,406.1 -15,998.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 104 -30 -68 -68 -66 -13 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   180.9% 144.6% 134.0% 114.1% 115.5% 117.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -49.6% -84.8% -66.4% -68.2% -59.7% -63.0% 0.0% 0.0%   ROI %   -55.1% -90.4% -69.1% -71.2% -68.6% -68.1% 0.0% 0.0%   ROE %   -43.2% -128.2% -135.0% -111.8% -126.3% -96.6% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   92.9% 18.3% -38.3% 52.5% 15.2% -27.7% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   196.6% -1.6% -81.6% 56.4% 34.1% -66.3% 0.0% 0.0%   Gearing %   0.0% 412.2% -251.1% 79.9% 196.3% -327.2% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 8.7% 10.4% 10.3% 6.5% 5.1% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   14.2 17.9 19.2 18.0 4.6 13.8 0.0 0.0   Current Ratio   14.2 17.9 19.2 18.0 4.6 13.8 0.0 0.0   Cash and cash equivalent   11,108.5 10,473.8 12,599.6 17,540.6 12,995.8 19,406.3 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   54.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   11,816.4 13,216.1 14,794.6 19,448.3 13,698.9 22,201.7 -4,653.9 -4,653.9   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -1,413 -2,840 -2,088 -7,869 -5,703 -7,999 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -1,413 -2,840 -2,088 -7,869 -5,703 -7,999 0 0   EBIT / employee   -1,413 -2,843 -2,092 -7,886 -5,720 -8,016 0 0   Net earnings / employee   -1,107 -2,308 -1,765 -7,432 -4,892 -6,906 0 0